Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis

Free AI-powered analysis and research for Apellis Pharmaceuticals, Inc. stock

Sector: Healthcare

Analyze Apellis Pharmaceuticals, Inc. (APLS) Stock

Apellis Pharmaceuticals, Inc. (APLS) is a leading company in the Healthcare sector. Use StockIQ's free analysis tool to get comprehensive insights into APLS stock performance, technical indicators, and AI-powered trading recommendations.

Get instant AI-powered analysis including technical indicators, fundamental analysis, risk assessment, and trading insights for Apellis Pharmaceuticals, Inc. stock.

📰 Latest Update

Biogen completes $5.3B Apellis Pharmaceuticals acquisition

Fri, May 15, 2026 at 11:44 AM UTC 2 min read

Biogen has successfully completed its acquisition of Apellis Pharmaceuticals for $5.3 billion. This strategic move enhances Biogen's portfolio in the neurology and ophthalmology sectors, potentially driving future growth and innovation. For investors, this acquisition could signal Biogen's commitment to expanding its therapeutic offerings and improving its competitive position in the biotech industry.

Read full article →

Why Analyze Apellis Pharmaceuticals, Inc. (APLS) with StockIQ?

• ✅ Free AI-powered analysis of Apellis Pharmaceuticals, Inc. (APLS) stock
• ✅ Real-time technical indicators for Apellis Pharmaceuticals, Inc. stock
• ✅ Comprehensive risk assessment for APLS
• ✅ No credit card required

People also watch